The US Food and Drug Administration (FDA) on Thursday approved Amgen’s Kanjinti (trastuzumab-anns), which is the fifth biosimilar to be approved for Roche’s Herceptin (trastuzumab) and 20th
Although none of the five Herceptin biosimilars have launched in the US yet, the first launches are expected soon. Roche has settled three court cases with Pfizer, Mylan and Biocon, and Celltrion and Teva. Roche also said
publicly that it expects competition sometime in the second half of 2019.
in March 2017 that it anticipates it will be the first company to launch a biosimilar to Herceptin in the US.
But none of the companies with approved Herceptin biosimilars have said specifically when a US launch will occur. Roche told Focus
in a statement: "We expect biosimilar versions of our medicines to start to become available in the United States this year."
In addition to Kanjinti, competitors include Pfizer’s Trazimera (trastuzumab-qyyp), approved in March
; Merck and Samsung Bioepis’ Ontruzant (trastuzumab-dttb), approved in January
; Celltrion and Teva’s Herzuma (trastuzumab-pkrb), approved in December 2018; and Mylan and Biocon’s Ogivri (trastuzumab-dkst), approved in December 2017
In Europe, according to Bernstein Research, Herceptin biosimilars are now capturing 38% share of the reference product market after 10 months of competition. There are three competitors for Herceptin in Europe: Ontruzant, which launched last March and has 12% of the market; Herzuma, which launched last May and has 18% of the market, and Amgen’s Kanjinti, which has captured 8% of the market.
Herceptin sales in 2018
totaled almost $7 billion worldwide for Roche. But Herceptin sales fell by 16% in Europe in 2018 because of the biosimilar launches, the company said.